爱博医疗拟6.83亿控股德美医疗，跨界运动医学赛道

Core Viewpoint - Aibono Medical has announced its entry into the sports medicine sector by acquiring a 68.31% stake in Demai Medical for 683 million yuan, utilizing a combination of acquisition loans and its own funds [1] Group 1: Acquisition Details - The acquisition of Demai Medical, established in 2016, is characterized by a high premium, with a valuation of 1.074 billion yuan, representing a 343.29% increase over its net asset value of 242 million yuan [2] - Demai Medical is recognized for its comprehensive product line in sports health, covering pre-surgery prevention, surgical treatment, and post-surgery rehabilitation, and has been included in the national high-value medical consumables procurement list [2] Group 2: Financial Performance - Aibono Medical reported a revenue of 1.41 billion yuan in 2024, a year-on-year increase of 48.22%, with a net profit of 387 million yuan, up 27.36% [3] - However, the company faces challenges due to a 60% price drop in artificial lenses following the implementation of national procurement policies, leading to a decline in profit margins [3] Group 3: Challenges and Opportunities - The sports medicine sector presents significant potential but is becoming increasingly competitive, with both foreign and domestic players vying for market share [5] - Aibono Medical plans to launch new products to counteract the impact of procurement policies, including a new artificial lens and a corneal reshaping lens, although these may not fully offset the profit decline from the artificial lens business [5] Group 4: Market Response - Following the announcement of the acquisition, Aibono Medical's stock price rose by 2.36%, reaching 62.4 yuan per share, with a total market capitalization of 12.068 billion yuan [6]